NeuroPace News

Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating

MT NewswiresMay 13 06:53 ET

NeuroPace's Strong Q1 Performance and Promising Growth Prospects Affirm Buy Rating

TipRanksMay 10 01:28 ET

NeuroPace Analyst Ratings

BenzingaMay 9 11:07 ET

Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), NeuroPace (NPCE) and Dynavax (DVAX)

TipRanksMay 9 06:30 ET

Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)

TipRanksMay 6 08:55 ET

NeuroPace Analyst Ratings

BenzingaMar 14 09:17 ET

Wells Fargo Upgrades NeuroPace to Overweight From Equalweight, Raises Price Target to $20 From $16

MT NewswiresMar 14 08:30 ET

NeuroPace Analyst Ratings

BenzingaMar 12 09:06 ET

NeuroPace Secures Buy Rating From Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers

TipRanksMar 6 23:15 ET

NeuroPace Analyst Ratings

BenzingaMar 6 12:14 ET

NeuroPace Financial Analysis: Hold Rating Maintained Amid Growth and Spending Concerns

TipRanksMar 6 06:28 ET

Lake Street Gives a Buy Rating to NeuroPace (NPCE)

TipRanksMar 4 09:05 ET

NeuroPace Analyst Ratings

BenzingaFeb 22 11:01 ET

NeuroPace Analyst Ratings

BenzingaJan 30 08:13 ET

Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Alignment Healthcare (ALHC) and 10x Genomics (TXG)

TipRanksJan 9 05:11 ET

NeuroPace Analyst Ratings

BenzingaDec 27, 2023 09:28 ET

NeuroPace Stock Poised for Continued Growth: Buy Rating Reaffirmed Amid Operational Successes and Market Expansion

TipRanksDec 27, 2023 09:16 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)

TipRanksDec 22, 2023 05:20 ET

Buy Rating on NeuroPace: Expanding Market Reach With RNS System Label Extension and Rapid Trial Progress

TipRanksDec 21, 2023 09:15 ET

Morgan Stanley Maintains Equal-Weight on NeuroPace, Raises Price Target to $9

BenzingaDec 4, 2023 07:43 ET